Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial to the prevention of atherosclerotic cardiovascular disease (ASCVD). However, many patients, especially those at very high ASCVD risk or with familial hypercholesterolemia (FH), do not achieve target LDL-C levels with statin mono...

Full description

Bibliographic Details
Main Authors: Farzahna Mohamed, Brett Mansfield, Frederick J. Raal
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Journal of Clinical Medicine
Subjects:
dyslipidemia
bempedoic acid
PCSK9 inhibitors
ANGPTL3 inhibitors
Online Access:https://www.mdpi.com/2077-0383/12/15/5082

Internet

https://www.mdpi.com/2077-0383/12/15/5082

Similar Items